Osobennosti vedeniya bol'nykh arterial'noy gipertoniey v sochetanii s dislipidemiey
- Авторлар: Malyshev P.P1, Tutunov V.S1
-
Мекемелер:
- Шығарылым: № 13 (2013)
- Беттер: 49-53
- Бөлім: Articles
- URL: https://journals.eco-vector.com/2073-4034/article/view/282290
- ID: 282290
Дәйексөз келтіру
Ашық рұқсат
Рұқсат берілді
Аннотация
The article pays attention to the combination of the significant cardiovascular risk factors as arterial hypertension and dyslipidemia, which justifies the need for a comprehensive therapeutic intervention for many patients. On the example of patients with metabolic syndrome, diabetes mellitus and familial combined hyperlipidemia, the indications for antihypertensive and lipid-lowering therapy, effective drug combinations, target values of blood pressure and lipid levels are discussed. The results of clinical studies on pharmacological efficacy, tolerability, and adherence to therapy in patients with arterial hypertension and dyslipidemia on the example of a fixed combination of amlodipine and atorvastatin are presented, indicating the effectiveness of this approach, « two drugs in one pill» for reducing cardiovascular risk in primary prevention.
Негізгі сөздер
Толық мәтін
Әдебиет тізімі
- Блинова Н.В., Саидова М.А., Тишина Е.В., Чазова Е.И. Метаболические и органопротективные эффекты комбинации амлодипина и аторвастатина у больных метаболическим синдромом // Системные гипертензии 2012. № 9. С. 38-43.
- Диагностика и коррекция нарушений липидного обмена с целью профилактики и лечения атеросклероза. Российские рекомендации (V пересмотр) // Российский кардиологический журнал № 2012. № 4(96).
- Mancia G, Fagard R, Narkiewicz K, et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 2013;34(28):2159-219.
- Sever PS, Dahl f B, Poulter NR, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 2003;361(9364):1149-58.
- Sever PS, Poulter NR, Dahlof B, et al. Antihypertensive therapy and the benefits of atorvastatin in the Anglo-Scandinavian Cardiac Outcomes Trial: lipid-lowering arm extension. J Hypertens 2009;27(5):947-54.
- Ridker PM, Danielson E, Fonseca FA, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008;359(21):2195-207.
- Scott R, O'Brien R, Fulcher G, et al. Effects of fenofibrate treatment on cardiovascular disease risk in 9,795 individuals with type 2 diabetes and various components of the metabolic syndrome: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. Diabetes Care 2009;32(3):493-98.
- Saha SA, Arora RR. Fibrates in the prevention of cardiovascular disease in patients with type 2 diabetes mellitus - a pooled meta-analysis of randomized placebo-controlled clinical trials. Int J Cardiol 2009;141:157-66.
- Veenkamp MS, de Graaf J, Bredie SJ, et al. Diagnosis of familial combined hyperlipidemia based on lipid phenotype expression in 32 families: results of a 5-year follow-up study. Arterioscler Thromb Vasc Biol 2002; 22:274-82.
- Hobbs FDR, Gensini G, Mancini GBJ, et al. International open-label studies to assess the efficacy and safety of single-pill amlodipine/ atorvastatin in attaining blood pressure and lipid targets recommended by country-specific guidelines: the JEWEL programme. Eur J Cardiovasc Prev Rehabil 2009;16:472-80.
- Simons LA, Ortiz M, Calcino G. Persistence with a single pill versus two pills of amlodipine and atorvastatin: the Australian experience, 2006 2010. MJA 2011;195:134-37.
- Chapman RH, Yeaw J, Roberts CS. Association between adherence to calcium-channel blocker and statin medications and likelihood of cardiovascular events among US managed care enrollees. BMC Cardiovascular Disorders 2010;10:29.
- Zamorano J, Edwards J. Combining antihypertensive and antihyperlipidemic agents - optimizing cardiovascular risk factor management. Integrated Blood Pressure Control 2011;4:55-71.
Қосымша файлдар
